drugset / Trial / NCT00190593

Raloxifene Use for The Heart

NCT00190593

Phase 3 Completed 10000 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

Timeline

Start
1998-06
Primary completion
Completion
2005-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Raloxifene Other / unclassified 60 mg